Previously developed models for predicting absolute risk of invasive epithelial ovarian cancer have included a limited number of risk factors and have had low discriminatory power (area under the receiver operating characteristic curve (AUC) < 0.60). Because of this, we developed and internally validated a relative risk prediction model that incorporates 17 established epidemiologic risk factors and 17 genome-wide significant single nucleotide polymorphisms (SNPs) using data from 11 case-control studies in the United States (5,793 cases; 9,512 controls) from the Ovarian Cancer Association Consortium (data accrued from 1992 to 2010). We developed a hierarchical logistic regression model for predicting case-control status that included imputation of missing data. We randomly divided the data into an 80% training sample and used the remaining 20% for model evaluation. The AUC for the full model was 0.664. A reduced model without SNPs performed similarly (AUC = 0.649). Both models performed better than a baseline model that included age and study site only (AUC = 0.563). The best predictive power was obtained in the full model among women younger than 50 years of age (AUC = 0.714); however, the addition of SNPs increased the AUC the most for women older than 50 years of age (AUC = 0.638 vs. 0.616). Adapting this improved model to estimate absolute risk and evaluating it in prospective data sets is warranted.
measures have been adopted clinically, making disease prevention and identification of high-risk women key to reducing mortality (1) .
Risk prediction models provide objective estimates for use in clinical decision-making, identification of highestrisk individuals who can benefit from preventive measures, development of preventive intervention studies at the population level, and creation of risk-benefit indices (3) . Risk prediction for EOC is challenging because of its rarity and the modest associations of most known risk factors, although several well-established risk factors have been identified. Oral contraceptive (OC) use (4), parity (5) , and tubal ligation (6, 7) are inversely associated with EOC risk; family history of breast and/or ovarian cancers are positively associated with risk (8) . Older age at menarche and use of menopausal hormone therapy (MHT) (particularly estrogen-only therapy) have been associated with a higher EOC risk, whereas breastfeeding and hysterectomy have been associated with a lower risk in some but not all studies (6, (9) (10) (11) (12) (13) (14) (15) (16) . Although results have been inconsistent, in a recent report of 12 population-based case-control studies, investigators concluded that aspirin use was associated with reduced EOC risk (17) . Further, endometriosis has been associated with risk of low-grade serous, endometrioid, and clear-cell EOC (18, 19) .
EOC risk models generally have low discrimination (area under the receiver operator characteristic curve (AUC) < 0.60), which may be partly due to exclusion of women who report premenopausal hysterectomy (with or without unilateral oophorectomy), incomplete inclusion of risk factors (e.g., tubal ligation), or the specific subpopulations in which the model was evaluated (e.g., women having a hysterectomy or women with symptoms) (20) (21) (22) (23) (24) (25) . Although some existing risk models specifically address risk among carriers of the mutation in the breast cancer 1 and breast cancer 2 genes (BRCA1 and BRCA2) (26, 27 ), mutations are rare in the general population; prior models for women of average risk have not considered genetic susceptibility. Given the 17 confirmed genetic variants related to EOC (28) (29) (30) (31) (32) (33) (34) , our objective was to develop and internally validate a relative risk prediction model for invasive EOC among women of average risk that incorporated all established and strongly probable epidemiologic risk factors and genetic data from 11 case-control studies in the United States that are members of the Ovarian Cancer Association Consortium (OCAC).
METHODS

Study populations and inclusion criteria
The analysis included 11 US-based case-control studies in the OCAC in which data were accrued from 1992-2010 (Table 1) (14, (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . All studies were population-based except for the Mayo Clinic Ovarian Cancer Case-Control Study (MAY), which was clinic-based; in that study, controls were women attending the Mayo Clinic's Departments of Family Medicine and General Internal Medicine for general medical examinations. All studies had ethics board approval and obtained written informed consent. Data were included for women who were 30 years of age or older at diagnosis (cases) or interview/reference date (controls), had no prior history of cancer (except nonmelanoma skin cancer), and self-identified as white, non-Hispanic; most women were confirmed to be of European ancestry by genetic analysis. Control subjects had to have at least 1 intact ovary, and case patients had invasive EOC. Most case patients (81%) were recruited within 1 year of diagnosis. After exclusions, the analysis included data from 5,793 invasive EOC cases and 9,512 controls. We randomly sampled 80% of the participants (n = 12,244) for estimation and model building; the remaining 20% (n = 3,061) were retained for independent validation.
Risk factor data
Risk factors from each study, as well as demographic and clinical variables, were submitted to the OCAC data coordination center at Duke University, where common coding schemes were applied; data were originally collected via questionnaire. Data on the following risk factors were available in the majority of studies: age at menarche (continuous years); OC use (ever vs. never); duration of OC use (continuous months); aspirin use (low dose, high dose, or irregular/no use); number of full-term pregnancies (continuous), number of non-full-term pregnancies (continuous variable; derived by subtracting parity from number of pregnancies); breastfeeding status (ever vs. never); duration of breastfeeding (continuous months); age at end of last pregnancy (continuous years); tubal ligation (yes vs. no); hysterectomy more than 1 year prior to diagnosis (cases) or interview/reference age (controls) (yes vs. no); endometriosis (yes vs. no); body mass index within 5 years of diagnosis/interview; menopause status at diagnosis (cases) or interview/reference age (controls) (premenopausal vs. postmenopausal); MHT use (ever vs. never); type of MHT (unopposed estrogen replacement therapy only vs. all other MHT use); history of breast cancer in a first-degree relative (yes vs. no); and history of ovarian cancer in a first-degree relative (yes vs. no). We considered additional potential risk factors (e.g., nonsteroidal antiinflammatory drug use, age at tubal ligation, age at menopause, and duration of MHT) that were ultimately not included because they were not significant predictors of EOC in preliminary models and were missing for a large percentage of participants. Because of frequency matching, age was included in all models to avoid bias (46) , as were random effects for study sites.
Genetic susceptibility data
The OCAC evaluated 23,239 single nucleotide polymorphisms (SNPs) in 43 individual studies that were grouped into 34 case-control strata; 2 previous genomewide association studies (GWAS) informed the OCACspecific SNP selection for the Collaborative Oncological Gene-Environment Study (COGS) (34) . Analysis of the GWAS and COGS genotype data resulted in identification and confirmation of 17 susceptibility loci (Web Table 1 , available at http://aje.oxfordjournals.org/) (28-34) that are 
Statistical analysis
We used generalized additive models (R package mgcv; R Foundation for Statistical Computing, Vienna, Austria) (47-49) with random effects for study site, fixed effects for categorical variables and SNPs, and smooth nonparametric functions for continuous variables for exploratory model fitting using subjects with complete data. Some evidence supports the idea that risk factor associations may vary by menopausal status (50) . However, because age at menopause was missing for 59% of the postmenopausal women and is difficult to determine for some women because of premenopausal hysterectomy and hormone use, we fit separate models for women younger than 50 years of age and women 50 years or older. The generalized additive models suggested that nonlinear functions of the continuous variables could be approximated with linear functions of the variables (P > 0.05) except for duration of OC use. The square root of OC use duration did not produce a significant increase in the deviance compared with using the spline terms (P = 0.2265), and a linear term for OC use duration was rejected (P = 0.0114). We retained linear terms with the original continuous variables except for duration of OC use, for which we used the square root transformation. Nulliparity was included as a term for interaction with all variables that were not defined for nulliparous women (age at last pregnancy, breastfeeding, and breastfeeding duration).
Some data were missing for all risk factors except age; 80% of the participants were missing information on at least 1 risk factor (Table 2). Rather than limit our analysis to participants with complete data or drop risk factors from the model, we developed a Bayesian model (51) that provided a coherent sequence of conditional models for casecontrol status, the risk factors, and indicators of whether they were missing (in the case of data not missing at random) (52) . Missing risk factors and indicators were modeled as functions of other risk covariates and of education level, smoking status, and alcohol use ( Table 3 ). The joint model specification for the risk factors and ovarian cancer status allowed all observed data to be incorporated and simultaneous inference for model parameters and missing data via Markov chain Monte Carlo (MCMC) using JAGS (Vienna, Austria) (53) . The increased sample size obtained by using participants with partial information can increase power, whereas the multiple imputations through MCMC provide valid confidence intervals for statistical inference by addressing uncertainty in the missing values and reducing bias induced by complete case analyses when data are not missing at random (54) .
The first stage Bernoulli models expressed the log odds of the probability of EOC (π_i) as
for the 2 groups (denoted by g) via a generalized linear mixed model with random effects for the 11 studies to account for differential baseline odds due to study design, as follows:
and random effects to account for birth cohort (c), as follows:
for the 6 hormonally-related covariates Z (i.e., indicator of OC use, square root of OC use duration, indicator of MHT use, indicator of type of MHT use, interaction of the indicator of hysterectomy with MHT use, and type of MHT use) to allow potential birth year differences due to formulation changes, and finally fixed effects for the remaining risk factors in X in each group (17 epidemiologic risk factors and the 17 SNPs). All of the group-specific means, β j g , for random-effects and fixed-effects coefficients for the other exposures were given independent normal prior distributions, with a mean β j and a prior standard deviation of 1, which reflected the expectation that population log odds ratios should be well within plus or minus 2 based on prior estimates and standard deviations from the literature. For the 17 SNPs, we used informative prior distributions based on log odds ratios from the GWAS and COGS samples independent from the 11 studies included in model development (Web Table 2 ). The hierarchical formulation allows coefficients to "shrink" to common coefficients across sites, cohorts, and age groups if significant variation is not present but provides flexibility to account for differences among groups while avoiding issues of multiple testing. Distributions for the missing data models are given in Table 3 . For example, missing SNPs were modeled using a multinomial model with the probabilities for the number of rare alleles given an informative Dirichlet prior distribution centered at genotype probabilities assuming Hardy-Weinberg equilibrium and a mass parameter in the Dirichlet equivalent to 1,000 observations; genotype probabilities were calculated using the minor allele frequencies estimated from GWAS and COGS samples from OCAC not used in this analysis (Web Table 2 ). Combined with genotype, other risk variables, and case-control status, missing SNPs were generated using their respective predictive distributions given the observed data and values of parameters at each iteration in the Markov chain.
Models with and without the SNPs were fit to the training data (random sample of 80%) and used to predict casecontrol status in the validation data (remaining 20%). Inference was based on 70,000 iterations of the MCMC algorithm. The first 20,000 iterations were used to assess convergence of the MCMC and the last 50,000 were used for inference with the training data and predictions in the validation set. Point estimates of log odds ratios were estimated by the median of the samples from the posterior distribution of each of the parameters; Bayesian 95% confidence intervals were obtained by taking the 2.5th percentile and 97.5th percentile of the estimated posterior distribution for each parameter (55) . Predictions for each participant in the training data were based on the mean of the posterior predictive distribution, which was estimated using the Monte Carlo average over posterior draws of missing predictors and parameters in equation 1. For comparison, we also fit a model that was adjusted for study site and age only (baseline model) and one that was adjusted for study site, age, and SNPs, omitting epidemiologic risk factors. e Missing genotype data were approximately the same across the 17 single nucleotide polymorphisms. The percentages of participants missing genotype data were as follows: 26% for training set controls, 27%-28% for training set cases and evaluation set controls, and 27% for evaluation set cases.
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Model validation
We compared the models with and without SNPs and with and without the epidemiologic variables (all models included reference age and study) based on their overall discriminatory accuracy and calibration in the independent validation data. We evaluated the discriminatory accuracy of the risk prediction models using the AUC from the receiver operating characteristics (ROC) curve. Predictive performance on the validation set was also assessed using calibration plots that compared the predicted risk (score) from the model to the observed proportions across groups defined by study sites, birth cohorts, age, and number of pregnancies.
RESULTS
The training set had 4,662 cases and 7,586 controls; the evaluation set had 1,131 cases and 1,926 controls ( Table 2 ). The average age was 57 years. In both the training and evaluation sets, case patients were less likely to use OCs, have been pregnant, and have had a tubal ligation than were controls and were more likely to have a family history of breast or ovarian cancer and to use MHT. The distribution of SNPs was similar to those observed in the GWAS and COGs data sets. Table 4 provides estimates of the log odds ratios (medians) and 95% Bayesian confidence intervals for the groupspecific coefficients from the hierarchical logistic regression model with the 17 SNPs; estimates from the model without the 17 SNPs were similar (Web Table 3 ). Most risk factors included in the model were statistically significant predictors among women younger than 50 years of age; however, in general, the directions of associations were comparable across groups. Notably, some associations were weaker among older women than among younger women, including duration of OC use, number of pregnancies, breastfeeding, family history of breast or ovarian cancers, endometriosis, tubal ligation, MHT use and type, and hysterectomy, whereas low-dose aspirin use showed a significant inverse association in women 50 years of age or older. Furthermore, more SNPs were significant for women 50 years or older, who comprised the majority of women in this study. Endometriosis, duration of OC use, tubal ligation, family history of breast or ovarian cancer, number of non-full-term pregnancies, and SNPS rs2072590, rs10088218 in 8q24, rs9303542, rs7651446 in 5p15, 
Risk Prediction for Ovarian Cancer 9
at Duke University on October 6, 2016
http://aje.oxfordjournals.org/ Downloaded from rs3814113, rs56318008, and rs183211 contributed significantly to all of the group-specific models.
The AUCs for models for all women, women younger than 50 years, and women 50 years and older both without and with SNPs included are shown in Figure 1A and 1B, respectively. The inclusion of the SNPs provided a small improvement (change in the AUC = 0.015) in predictions for the validation data in terms of AUC for all women, with the biggest improvement for women 50 years of age and older (0.026 increase). Among all women, the AUC was 0.664 in the model with SNPs and 0.649 in the model without SNPs (but including epidemiologic factors), which is a marked improvement over the AUC for the models with age and study site alone (AUC = 0.563) and those with age, study site, and the 17 SNPs (AUC = 0.600) ( Table 5 ). The posterior probability that the AUC for the full model with SNPs and epidemiologic factors is better than the AUC for the model with age, study site, and SNPs alone was 99.8%, whereas there was a 70% chance that the addition of SNPs improved AUC over the model with age, study site, and epidemiologic factors. The best predictive power was obtained for women younger than 50 years: The AUCs were 0.714 and 0.713 in the models with and without the SNPs, respectively. Lower AUCs were observed in women 50 years of age or older (with SNPs, AUC = 0.638; without SNPs, AUC = 0.612). Finally, we generated a target ROC curve with an AUC of 0.75 for a widely accepted clinically actionable discrimination by sequentially adding hypothetical SNPs generated with a minor allele frequency of 0.20 and a log odds ratio of 0.15 (within the range of validated SNPS for EOC) until the AUC exceeded 0.75. Under this setting, on average 58 additional SNPS would be needed (95% confidence interval: 39, 79) to increase the AUC from 0.66 to 0.75. Figure 2 and Web Figure 1 suggest that the model is wellcalibrated across risk score deciles, studies, birth cohorts, age, and number of pregnancies.
DISCUSSION
Our validated relative risk prediction model for EOC includes an extensive list of established non-genetic risk factors for ovarian cancer and 17 novel genetic variants. We divided the data set of 5,793 cases and 9,512 controls of non-Hispanic, European ancestry in an 80:20 ratio for use in independent modeling and evaluation analyses. Overall, the model's predictive capacity was modest, and epidemiologic factors contributed to the increase in the AUC substantially more than did the SNPs. The methodology for imputation developed here may be adapted for prospective validation.
Previous ovarian cancer risk prediction analyses have included fewer than 1,000 cases in any given phase of model development or validation (23, 24) . Our larger sample size provided ample power for stratification by age and permitted us to include a much larger number of accepted epidemiologic risk factors, as well as 17 genetic loci. This and imputation of missing data provided the power necessary to detect and estimate higher-order interaction effects. The model includes an interaction between MHT use and hysterectomy status dependent on age.
In contrast to previous models, ours was a joint model for disease status, risk factors, and missingness. A strength Receiver operating characteristic curve for models A) without and B) with single nucleotide polymorphisms (SNPs). The receiver operating characteristic (ROC) curve plots the true positive fraction (i.e., sensitivity) versus the false positive fraction (i.e., 1-specificity) at various threshold settings. The ROC curve in A represents the relative risk prediction model containing age, study site, and 17 risk factors; the ROC curve in B represents the full relative risk prediction model containing the variables in A plus 17 confirmed genetic susceptibility variants. For each model, 3 ROC curves are presented for women grouped by age: all ages, women younger than 50 years of age, and women 50 years of age or older.
The area under the curve, a measure of discriminatory power equivalent to the C statistic in binary models, is presented for each ROC curve. A fourth hypothetical target ROC curve is depicted based on adding additional hypothetical SNPs with a minor allele frequency of 0.20 and log odds ratio of 0.15 (similar to the current data) until the area under the curve is 0.75 or more; on average, 58 additional SNPs would be needed (95% confidence interval: 39, 79).
of our approach was the use of MCMC methods that allow for simultaneous inference for missing data and model parameters. This allowed us to include all participants in the analysis while correctly accounting for the observed sample sizes in interval and error estimates of odds ratios. This is critical when variables, such as hysterectomy status, are not missing at random and would lead to biased inferences, including complete-case analysis (54) . The hierarchical framework also permits parsimonious adjustment for birth cohort effects in hormonal exposures, such as OC and MHT use, for which formulations have changed over time.
To date, absolute risk prediction models for ovarian cancer have achieved moderate discriminatory accuracy in the general population. A recent model, which included firstdegree family history of breast or ovarian cancer, duration of MHT use, parity, and duration of OC use and was developed and externally validated among women older than 50 years of age, had an AUC of 0.59 (23) . The best model from the Nurses' Health Studies included duration of ovulation (age (for premenopausal women) or age at menopause minus age at menarche minus 1 year per pregnancy and years of OC use), duration of menopause, and tubal ligation; the overall AUC for the model predicting ovarian cancer was approximately 0.60 (24) . Our full model obtained higher overall predictive accuracy (AUC = 0.664), albeit estimated in a case-control setting, in part because more established risk factors were included and we allowed for associations to vary by strata in the population (age), as well as birth cohorts.
The predictive ability of the model was substantially higher for younger women (AUC = 0.714) than for older women (AUC = 0.638), despite the increase in incidence of ovarian cancer with age. This is consistent with the Rosner risk prediction model (24) , in which the AUCs generally were higher for women younger than 50 years of age. One reason for the improved prediction in younger women is that many of the risk factors occur during premenopause and appear to have stronger associations in younger women, perhaps in part because the exposure to the risk factors is more proximal (50) . Our results are consistent with those from studies of individual risk factors that suggested, for example, that the inverse association with hysterectomy, OC use, and tubal ligation attenuate with increasing time since last use (or surgery) (4, 6, 50) .
Recent efforts to improve risk estimation have focused on common genetic variation. However, the addition of common SNPs to risk prediction models has not yet resulted in dramatically improved discriminatory accuracy in real or simulated data scenarios (56) (57) (58) . Our findings are consistent with this; addition of the 17 confirmed SNPs improved the AUC of the model that incorporated epidemiologic risk factors by a small amount (with SNPs, AUC = 0.664; without SNPs, AUC = 0.649). Our model pertains to women of average baseline risk, and mutation status of highly penetrant susceptibility genes such as BRCA1 and BRCA2 was not included because these data were not available. Although the model accounts for family history of breast and ovarian cancer, the inclusion of the mutation status and other high penetrant rare variants may improve prediction in future efforts. However, even strongly associated risk factors may only modestly improve upon a risk model's discriminatory accuracy (59) , and a very large number of susceptibility SNPs are required to make a substantial impact because of their small relative risks (60) . Our simulation results suggest that an additional 39-79 SNPs may be needed to increase the AUC to a clinically actionable discriminatory value of 0.75. This is similar to observations for breast cancer, for which a 3-4 unit increase can be achieved with addition of 60-70 SNPs (56, 58, (61) (62) (63) (64) .
The model may be improved by extension to predict histologic subtypes of EOC, because risk factor associations may vary by histology (19) . Further gains in predictive accuracy may accompany discovery and inclusion of The calibration plot represents the agreement between the average predicted probability of epithelial ovarian cancer (i.e., risk score) and observed outcomes (i.e., relative frequency of cases) in the full risk prediction model containing age, study site, 17 risk factors, and 17 confirmed genetic susceptibility variants for women included in the analysis. Women were divided into 10 bins determined by increasing risk (0.10 long). The vertical and horizontal bars reflect uncertainty in the average predicted risk and mean under a Bernoulli model, respectively. additional novel risk factors. In breast cancer, the addition of sex hormones and mammographic density added substantially to risk prediction models (65, 66) . Finally, these results may not be generalizable to other racial/ethnic groups or to women in other countries. Our model was developed and internally validated among participants from case-control studies. Although this study design may be subject to misclassification and selection bias, the studies were predominantly populationbased, and our associations are similar in direction and magnitude to those observed in cohort studies. To be clinically meaningful, the relative risk estimates must be combined with a model of age-specific baseline population risk to provide estimates of absolute risk. Hierarchical models provide a natural framework for integrating relative risk estimates from this study-and propagating their uncertainty -into future models for absolute risk within prospective studies.
